US 11,905,325 B2
Recombinant polypeptide production method
Hisahiro Tabuchi, Tokyo (JP); and Tomoya Sugiyama, Tokyo (JP)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP)
Filed by CHUGAI SEIYAKU KABUSHIKI KAISHA, Tokyo (JP)
Filed on Apr. 23, 2021, as Appl. No. 17/239,175.
Application 17/239,175 is a division of application No. 14/008,791, granted, now 11,028,149, previously published as PCT/JP2012/058577, filed on Mar. 30, 2012.
Claims priority of application No. 2011-082002 (JP), filed on Apr. 1, 2011.
Prior Publication US 2021/0246193 A1, Aug. 12, 2021
Int. Cl. C07K 16/00 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01)
CPC C07K 16/00 (2013.01) [C12N 15/113 (2013.01); A61K 38/00 (2013.01); C07K 16/2866 (2013.01); C07K 16/303 (2013.01); C07K 2317/14 (2013.01); C12N 2310/14 (2013.01); C12N 2510/02 (2013.01)] 7 Claims
 
1. An isolated cell capable of producing an antibody, said cell comprising a vector comprising a nucleic acid molecule selected from:
(a) a DNA consisting of the sequence of any one of SEQ ID NOs: 2 to 16 and 29;
(b) a DNA consisting of 19 to 25 sequential nucleotides in the sequence of SEQ ID NO: 2;
(c) an RNA that is a transcript of (a) or (b);
(d) a DNA or RNA consisting of a sequence that can bind to 19 to 25 sequential nucleotides in the sequence of SEQ ID NO: 2 by base pairing; and
(e) a DNA consisting of a sequence identical to the sequence of any one of SEQ ID NOs: 1 to 16 and 29, except for one nucleotide.